Viral safety of human plasma-derived medicinal products: Impact of regulation requirements

Transfusion Medicine Reviews

Volumn 27, Issue 3, 2013, Pages 179-183

  Velthove, Karin J ^a   Over, Jan ^a   Abbink, Kristiena ^a,b   Janssen, Mart P ^c  

^a CENTRAL LABORATORY   (Netherlands)

^b KAPQS BV   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BIOSAFETY; BLOOD DONOR; BLOOD TRANSFUSION; BLOODBORNE BACTERIUM; DISEASE TRANSMISSION; DONOR; DONOR SELECTION; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INCIDENCE; INFECTION CONTROL; INFECTION RISK; PRACTICE GUIDELINE; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SCREENING TEST; VIRAL CONTAMINATION; VIRUS CONCENTRATION; VIRUS INACTIVATION; VIRUS TRANSMISSION;

EID: 84880749862     PISSN: 08877963     EISSN: 15329496     Source Type: Journal    
DOI: 10.1016/j.tmrv.2013.05.002     Document Type: Article

References (29)

1. Burnouf T. Modern plasma fractionation. Transfus Med Rev 2007, 21:101-117.
2. Garcia-Lloret M, McGhee S, Chatila TA. Immunoglobulin replacement therapy in children. Immunol Allergy Clin North Am 2008;28:833-49, ix.
3. Hooper JA. Intravenous immunoglobulins: evolution of commercial IVIG preparations. Immunol Allergy Clin North Am 2008;28:765-78, viii.
4. Konkle B.A., Kessler C., Aledort L., Andersen J., Fogarty P., Kouides P., et al. Emerging clinical concerns in the ageing haemophilia patient. Haemophilia 2009, 15:1197-1209.
5. Makris M., Van Veen J.J., Maclean R. Warfarin anticoagulation reversal: management of the asymptomatic and bleeding patient. J Thromb Thrombolysis 2010, 29:171-181.
6. Buddeberg F., Schimmer B.B., Spahn D.R. Transfusion-transmissible infections and transfusion-related immunomodulation. Best Pract Res Clin Anaesthesiol 2008, 22:503-517.
7. Alter H.J. Pathogen reduction: a precautionary principle paradigm. Transfus Med Rev 2008, 22:97-102.
8. Azzi A., Morfini M., Mannucci P.M. The transfusion-associated transmission of parvovirus B19. Transfus Med Rev 1999, 13:194-204.
9. The European Medicines Agency. Committee for medicinal products for human use (CHMP). Guideline on epidemiological data on blood transmissible infections. For inclusion in the Guideline on the Scientific data requirements for a Plasma Master File (EMEA/CPMP/BWP/3794/03). 20-JAN-2005.
10. The European Medicines Agency. Committee for medicinal products for human use (CHMP). Guideline on epidemiological data on blood transmissible infections (EMA/CHMP/BWP/548524/2008). 22-APR-2010.
11. The European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Guideline on plasma-derived medicinal products (EMA/CHMP/BWP/706271/2010). 21-JUL-2011.
12. Allain J.P., Bianco C., Blajchman M.A., Brecher M.E., Busch M., Leiby D., et al. Protecting the blood supply from emerging pathogens: the role of pathogen inactivation. Transfus Med Rev 2005, 19:110-126.
13. Berger M., Pinciaro P.J., Althaus A., Ballow M., Chouksey A., Moy J., et al. Efficacy, pharmacokinetics, safety, and tolerability of Flebogamma 10% DIF, a high-purity human intravenous immunoglobulin, in primary immunodeficiency. J Clin Immunol 2010, 30:321-329.
14. Bershad E.M., Suarez J.I. Prothrombin complex concentrates for oral anticoagulant therapy-related intracranial hemorrhage: a review of the literature. Neurocrit Care 2010, 12:403-413.
15. van der Meer J.W., van Beem R.T., Robak T., Deptala A., Strengers P.F. Efficacy and safety of a nanofiltered liquid intravenous immunoglobulin product in patients with primary immunodeficiency and idiopathic thrombocytopenic purpura. Vox Sang 2011, 101:138-146.
16. Hofstra J.J., Kleine Budde I., van Twuyver E., Choi G., Levi M., Leebeek F.W.G., et al. Treatment of hereditary angioedema with nanofiltered C1-esterase inhibitor concentrate (Cetor): multi-centre phase II and III studies to assess pharmacokinetics, clinical efficacy and safety. Clin Immunol 2011, 142:280-290.
17. Janssen M.P., Over J., van der Poel C.L., Cuijpers H.T., van Hout B.A. A probabilistic model for analyzing viral risks of plasma-derived medicinal products. Transfusion 2008, 48:153-162.
18. Hahne S.J., de Melker H.E., Kretzschmar M., Mollema L., Van der Klis F.R., Van der Sande M.A., et al. Prevalence of hepatitis B virus infection in the Netherlands in 1996 and 2007. Epidemiol Infect 2012, 140:1469-1480.
19. Weimer T., Streichert S., Watson C., Groner A. Hepatitis A virus prevalence in plasma donations. J Med Virol 2002, 67:469-471.
20. Meldingsplicht infectieziekten; Leeftijdsverdeling in jaren per infectieziekte: Hepatitis A. 2013. Accessed on February 11, 2013.
21. Fields virology. 5 ed. Philadelphia: Wolters Kluwer, Lippincott William & Wilkins; 2007.
22. Bower W.A., Nainan O.V., Han X., Margolis H.S. Duration of viremia in hepatitis A virus infection. J Infect Dis 2000, 182:12-17.
23. Zou S., Stramer S.L., Dodd R.Y. Donor testing and risk: current prevalence, incidence, and residual risk of transfusion-transmissible agents in US allogeneic donations. Transfus Med Rev 2012, 26:119-128.
24. Klein H.G. How safe is blood, really?. Biologicals 2010, 38:100-104.
25. Berg H.P. Quantitative safety goals and criteria as a basis for decision making. Reliability: Theory & Applications 2010, 5:62-78.
26. Duijm N.J. Acceptance criteria in Denmark and the EU. Danmarks Tekniske Universitet, Institut for Planlægning, Innovation og Ledelse 2008, Danish Ministry of the Environment, Miljøprojekt, [Environmental Project No.1269 2009].
27. Det Norske Veritas Final report-risk acceptance criteria for technical systems and operational procedures 2010, Ltd. Stockport, Cheshire, United Kingdom, [Report No: 24127328/03 Rev: 02].
28. The Health and Safety Executive (HSE) The tolerability of risk from nuclear power stations 1988, [United Kingdom].
29. State of New South Wales through the Department of Planning HIPAP 4: risk criteria for land use safety planning 2011.